Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 2/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM4B | O94953 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16292659 | 1.00 | SIRT2 (0.34) | SIRT2METALDH1A1KDM5CKDM5B | |
| SCHEMBL16294292 | 0.83 | SIRT2 (0.38) | SIRT2ALDH1A1KDM5CKDM5BKDM5A | |
| SCHEMBL16293836 | 0.78 | KDM5B (0.37) | ALDH1A1KDM5CKDM5BKDM5AKDM5D | |
| SCHEMBL16293837 | 0.78 | KDM5B (0.37) | ALDH1A1KDM5CKDM5BKDM5AKDM5D | |
| SCHEMBL18880294 | 0.78 | KDM5B (0.33) | ALDH1A1KDM5CKDM5BKDM5AKDM5D | |
| SCHEMBL18880304 | 0.76 | CACNA1B (0.38) | ALDH1A1 | |
| SCHEMBL16303336 | 0.76 | CACNA1B (0.38) | ALDH1A1 | |
| SCHEMBL16293754 | 0.76 | CACNA1B (0.38) | ALDH1A1 | |
| SCHEMBL16292658 | 0.75 | KDM5B (0.40) | ALDH1A1KDM5CKDM5BKDM5AKDM5D | |
| SCHEMBL18880295 | 0.74 | KDM5B (0.51) | ALDH1A1KDM5CKDM5BKDM5AKDM5D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | SIRT2 592/4885MET 2008/4885ALDH1A1 1536/4885 |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | SIRT2 592/4885MET 2008/4885ALDH1A1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.